Clinical trials: Phase 1
Dry Eye Disease
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage…
- Trial name
- NCT04762355
- Testing
- Palovarotene, Vehicle
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Clementia Pharmaceuticals Inc.
HIV Antibodies
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Background: The experimental product in this study, N6LS, is a human monoclonal antibody. Antibodies are one way that the human body fights infection. Monoclonal means that all the antibodies in the product are the same.
- Trial name
- VRC 609 (NCT03538626)
- Testing
- VRC-HIVMAB091-00-AB, rHuPH20
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteer
Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults
The primary objective of Part 1 of the study is to evaluate the safety and tolerability of S-648414 after administration of a single oral dose of S-648414 in healthy adult study participants.
- Trial name
- NCT04147715
- Testing
- S-648414, Midazolam, Dolutegravir
- Where
- 2 sites in United States, Japan
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Shionogi
West Nile Virus
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
The primary purpose of this phase 1, double-blind, cohort study is to evaluate the safety, tolerability, and pharmacokinetics of escalating doses of MGAWN1 administered as a single intravenous (IV) infusion to healthy adults.
- Trial name
- NCT00515385
- Testing
- MGAWN1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MacroGenics
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin.
- Trial name
- NCT01325415
- Testing
- NKTR-118, moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are: Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple…
- Trial name
- NCT06891287
- Testing
- RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- RANI Therapeutics
Healthy Volunteers, Pharmacokinetics of ASP1941
Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults
This is a study of the pharmacokinetic profile and safety and tolerability of ASP1941after repeat dosing and the effect of ASP1941 on glucose levels in non elderly and elderly healthy adult male and female subjects.
- Trial name
- NCT01678287
- Testing
- ASP1941
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabete Type 2
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of…
- Trial name
- BRIDGE-BR (NCT07518121)
- Testing
- Efsubaglutide Alfa Injection
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Hyperlipidemias
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal…
- Trial name
- NCT07322016
- Testing
- HRS-1301 Tablet
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Healthy
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects
- Trial name
- NCT04250506
- Testing
- Daridorexant, Moxifloxacin
- Where
- Czechia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy
Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine
Malaria is responsible for over 2 million deaths each year. The development of an efficient vaccine would present by far the best solution for solving this disastrous situation.
- Trial name
- LSA-3-rec (NCT00509158)
- Testing
- arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant, arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Health Adults, Temporal Interference Stimulation
Safety and Feasibility of Temporal Interference Brain Stimulation for Treatment in Psychiatric Disorders
The goal of this clinical trial is to validate if temporal interference brain stimulation (TIBS) is safe in healthy volunteers aged 20 to 65.
- Conditions
- Health Adults, Temporal Interference Stimulation, Safety and Effectiveness, Crossover Study
- Trial name
- NCT07179848
- Testing
- Temporal Interference Stimulation - Treatment first
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Healthy Subjects (HS)
A Phase I Clinical Trial of JH013 Injection
This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects
- Trial name
- NCT06633055
- Testing
- JH013 injection
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Renal Insufficiency
PF-04634817 Renal Impairment Study
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment.
- Trial name
- NCT01791855
- Testing
- PF-04634817
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Study of RG7667 in Healthy Volunteers
This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers.
- Trial name
- NCT01496755
- Testing
- RG7667
- Where
- 5 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Renal Impairment
Glasdegib Renal Impairment Study
The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
- Trial name
- NCT03596567
- Testing
- Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg dose in moderate renal impairment subjects, Glasdegib single 100 mg dose in severe renal impairment subjects
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Phase 1 Study of MGD010 in Healthy Subjects
The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
- Trial name
- NCT02376036
- Testing
- MGD010, Hepatitis A vaccine
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- MacroGenics
Healthy
Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects
A three (3) part study to evaluate the safety, tolerability and PK of RDN-929
- Trial name
- NCT03668314
- Testing
- RDN-929, RDN-929 TBD dose
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Healthy Volunteers Study
Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)
Drug-drug interaction study of Digoxin and AT-527 (R07496998)
- Trial name
- NCT05137626
- Testing
- AT-527 + digoxin
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
This phase I trial is studying the side effects and best dose of alemtuzumab when given together with bendamustine hydrochloride in treating patients with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Conditions
- Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00947388
- Testing
- Bendamustine Hydrochloride, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.